News ASCO26: AZ triplet makes waves in frontline liver cancer EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.
News CEPI puts $60m behind three Ebola vaccine candidates Moderna has been awarded $50m from CEPI for a Bundibugyo ebolavirus vaccine candidate, with funding also made available to two other candidates.
News Servier wagers $2.65bn on Edgewise muscular dystrophy drug Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.
News ASCO26: Verzenio gives hope of liposarcoma treatment advance The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.
News DHSC lauds benefits of single patient record ahead of debate The NHS digital single patient record (SPR) could result in 20,000 fewer A&E visits in England per year and save £20m a year, says the UK government.
News ASCO26: Could AL amyloidosis see a new crop of therapies? Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.